Related Experiment Videos
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"]
1Département de Médecine, Université de Liège.
Insights
Pravastatin significantly reduced coronary heart disease deaths and cardiovascular events in patients with coronary heart disease. This cholesterol-lowering statin therapy showed benefits even for individuals with initially normal cholesterol levels.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
- Effective secondary prevention strategies are crucial for managing patients with existing CHD.
- The role of statins in patients with varying cholesterol levels requires further elucidation.
Purpose of the Study:
- To evaluate the efficacy of pravastatin in reducing cardiovascular events and mortality in patients with CHD.
- To determine if the benefits of pravastatin extend to patients with baseline cholesterol levels considered normal.
Main Methods:
- The LIPID study was a randomized, double-blind, placebo-controlled trial involving 9014 patients with CHD.
- Participants had total cholesterol levels ranging from 155 to 271 mg/dl.
- Patients were followed for a mean of 6.1 years, receiving either pravastatin (40 mg/day) or a placebo.
Main Results:
- Pravastatin significantly reduced CHD death rate by 24% (p < 0.001), overall mortality by 22%, and cardiovascular outcomes by 20-29%.
- These benefits were observed across all initial cholesterol concentrations.
- Significant reductions in CHD death or nonfatal myocardial infarction were noted even with total cholesterol < 213 mg/dl and LDL cholesterol < 135 mg/dl.
Conclusions:
- Pravastatin is effective in secondary prevention for patients with CHD, lowering mortality and cardiovascular event rates.
- The cardioprotective effects of pravastatin are evident even in patients with baseline cholesterol levels within the 'normal' range.
- These findings support the use of statin therapy for secondary prevention in a broad spectrum of CHD patients.
Abstract:
The LIPID study is a placebo-controlled, double-bind, randomized trial, performed in 9014 patients with coronary heart disease and total cholesterol levels of 155 to 271 mg/dl. After a mean follow-up of 6.1 years, patients receiving pravastatin (40 mg/day) had significantly (p < 0.001) lower death rate from coronary heart disease (24%), lower overall mortality (22%) and lower incidence of all cardiovascular outcomes (20 to 29% depending on the event). Interestingly enough, the reduction in death from coronary heart disease or nonfatal myocardial infarction was observed whatever the initial cholesterol concentration, and already significant if total cholesterol was < 213 mg/dl and LDL cholesterol was < 135 mg/dl. Thus, in secondary prevention, the favourable effect of the statin on the coronary heart disease outcomes is observed even in case of initial cholesterol levels yet considered as "normal".